Top 7 Cancer Indications - Therapeutic & Competitive Insights

SUMMARY

Executive Summary

With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the anti-cancer arena. The report is structured according to the top 7 cancer indications: Breast cancer, Colon/colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, and Prostate cancer. No other report will provide a likewise structure and analysis. The report not only provides a close to complete structure of each cancer indication field, it as well describes the progress of hundreds of drugs in development. Information on most company related activities are included. More than 250 companies are involved in developing new drugs within the top seven cancer indications.

In the report BioSeeker does not only describe and analyze the latest years of progress but as we well provide an insight and framework to understand the complex field of cancer therapeutics. The report provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase II and III development, together with general descriptions on drugs and targets. In total we have selected more than 360 drug candidates to analyze. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report:

• Progress analysis of Top 7 Cancer Indications, including players, drugs, clinical progress and pitfalls
  • Breast Cancer
  • Colon/colorectal cancer
  • Leukemia
  • Lung cancer
  • Lymphoma
  • Melanoma
  • Prostate Cancer
• Includes more than 250 drug developing companies
• Includes more than 360 candidate drugs
• The report includes more than 160 Tables, 200 Boxes and 600 high quality references

Key reasons to read this report:

• Understand the clinical and strategic challenges to the commercialization of drugs within the top 7 cancer indications
• Assess opportunities and risks for the continued development of drugs in seven major cancer indications
• Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

TABLE OF CONTENTS

TOP 7 CANCER INDICATIONS

THERAPEUTIC & COMPETITIVE INSIGHTS

1. EXECUTIVE SUMMARY

2. TABLE OF CONTENTS

• 2.1 LIST BOXES
• 2.2 LIST OF FIGURES
• 2.3 LIST TABLES

3. METHODOLOGY

4. LUNG CANCER

• 4.1 INTRODUCTION
  • 4.1.1 Disease Definition
  • 4.1.2 Etiology & Pathophysiology
  • 4.1.3 Prognosis
  • 4.1.4 Epidemiology
• 4.2 CURRENT TREATMENT STRATEGIES
  • 4.2.1 Treatment Guide Lines
• 4.3 PROGRESS IN CURRENT TREATMENT STRATEGIES
  • 4.3.1 Improvements adding microtubule inhibitor
  • 4.3.2 Improvement of disease related symptoms in elderly patients
  • 4.3.3 Toxicity profile favored
  • 4.3.4 A new formula
  • 4.3.5 Monotherapy?
  • 4.3.6 Failed to demonstrate a survival advantage
  • 4.3.7 Reduction in mortality risk
• 4.4 KEY DRUG STRATEGIES IN LUNG CANCER
  • 4.4.1 Therapeutic Type, Targets & Mechanisms
• 4.5 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
  • 4.5.1 Grade 4 adverse events
  • 4.5.2 No new remarks
  • 4.5.3 No significant effect on overall survival
  • 4.5.4 Bristol Myers Squibb entered into an agreement
  • 4.5.5 Many uncertainties remain
  • 4.5.6 Development terminated
  • 4.5.7 Continuing Enrollment
  • 4.5.8 Apoptotic inducer
  • 4.5.9 Fully-human monoclonal antibody
  • 4.5.10 Eagerly awaiting data
  • 4.5.11 Mutations and response
  • 4.5.12 Statistically and clinically significant survival advantage
  • 4.5.13 Anti-idiotypic monoclonal antibody
  • 4.5.14 Shift in the development focus
  • 4.5.15 Sensitizer
  • 4.5.16 Treatment in earlier-stage cancer could be more effective
  • 4.5.17 Discontinued radiosensitizer
  • 4.5.18 Improvement in chemoradiotherapy
  • 4.5.19 Progress on HDAC inhibitor
  • 4.5.20 Progress Analysis Carboxyamidotriazole
  • 4.5.21 Chemotherapy naive subjects
• 4.6 PROGRESS PROFILES ON APPROVED DRUGS
  • 4.6.1 Docetaxel
  • 4.6.2 Vinorelbine
  • 4.6.3 Gemcitabine
  • 4.6.4 Paclitaxel
  • 4.6.5 Pemetrexed
  • 4.6.6 Gefitinib
  • 4.6.7 Erlotinib

5. COLON CANCER

• 5.1 INTRODUCTION
  • 5.1.1 Epidemiology
  • 5.1.2 Disease Definition
  • 5.1.3 Prognosis for Colorectal Cancer by Stage
• 5.2 CURRENT TREATMENT STRATEGIES
  • 5.2.1 Treatment Guide Lines
• 5.3 PROGRESS IN CURRENT TREATMENT STRATEGIES
  • 5.3.1 A 50% Increase in Sales!
  • 5.3.2 Topoisomerase inhibitor in First-line and Second-line Treatment
  • 5.3.3 Fast Way to Approval
  • 5.3.4 A Significant Reduction in the Risk of Death
  • 5.3.5 Mice and Men
  • 5.3.6 The Very Base
• 5.4 KEY DRUG STRATEGIES IN CRC
  • 5.4.1 Therapeutic Type, Targets & Mechanisms
  • 5.4.2 An Answer to Drug Resistance
  • 5.4.3 Novel Therapies at the Gate
  • 5.4.4 Tumor Vascularization & Antivascular Agents
  • 5.4.5 Anti-angiogenesis: Therapeutic Strategies
  • 5.4.6 Single Agent Therapy: Poorly Active in Advanced Tumors
  • 5.4.7 Synergistic Effects with Cytotoxic Therapies
  • 5.4.8 Vascular Targeting Agents
  • 5.4.9 Vaccines
  • 5.4.10 Tumor antigens
  • 5.4.11 The Cell Vaccines Strategy
  • 5.4.12 Potent antigen presenting cells
  • 5.4.13 Emerging strategies
  • 5.4.14 Better-characterized antigens
• 5.5 COMPETITIVE LANDSCAPE IN CRC DRUG DEVELOPMENT
  • 5.5.1 We are in the Lead
  • 5.5.2 Amgen
  • 5.5.3 Novartis and Schering
  • 5.5.4 OSI, Genentech, Hoffmann La Roche & Pfizer
  • 5.5.5 Sanofi-Aventis
• 5.6 CURRENT CRC DRUG DEVELOPMENT
  • 5.6.1 Chemotherapy and Cytotoxic Drugs - A strategy reborn
  • 5.6.2 Progress Analysis: CoFactor
  • 5.6.3 Progress Analysis: Trabectedin (ET-743)
  • 5.6.4 Progress Analysis: Pemetrexed
  • 5.6.5 Progress Analysis: TS-1
  • 5.6.6 Progress Analysis: Edotecarin
  • 5.6.7 Progress Analysis: Aroplatin
  • 5.6.8 Progress Analysis: Ixabepilone
  • 5.6.9 EGF-R Inhibition and Other Signal Transduction Inhibitors
  • 5.6.10 Progress Analysis: Panitumumab
  • 5.6.11 Progress Analysis: Erlotinib (Tarceva)
  • 5.6.12 Progress Analysis: Gefitinib (Iressa)
  • 5.6.13 Progress Analysis: Pelitinib
  • 5.6.14 Progress Analysis: Sorafenib
  • 5.6.15 Signal Transduction Inhibitors in CRC
  • 5.6.16 Progress Analysis: BIO-117
  • 5.6.17 Progress Analysis: PD 0325901
  • 5.6.18 Antiangiogenetic- A team of players
  • 5.6.19 Progress Analysis: Vatalanib
  • 5.6.20 Progress Analysis: Thalidomide
  • 5.6.21 Progress Analysis: AMG 706
  • 5.6.22 Progress Analysis: Combretastatin A4 prodrug
  • 5.6.23 Progress Analysis: MBT 0206
  • 5.6.24 Progress Analysis: MEDI 522
  • 5.6.25 Progress Analysis: Tetrathiomolybdate
  • 5.6.26 Progress Analysis: WX-UK1
  • 5.6.27 COX-2 Inhibitors - What will become of us?
  • 5.6.28 Progress Analysis: P 54
  • 5.6.29 Progress Analysis: CV-247
  • 5.6.30 Apoptosis: An approach with a future
  • 5.6.31 Progress Analysis: HGS-ETR1
  • 5.6.32 Progress Analysis: APLIDIN
  • 5.6.33 Progress Analysis: VELCADE
  • 5.6.34 Progress Analysis: TELCYTA
  • 5.6.35 Progress Analysis EPO 906
  • 5.6.36 Progress Analysis: BIO-145
  • 5.6.37 Progress Analysis: Genasense
  • 5.6.38 Progress Analysis: Rexin-G
  • 5.6.39 Progress Analysis: Indisulam
  • 5.6.40 Progress Analysis: Seliciclib
  • 5.6.41 Progress Analysis: SYMADEX
• 5.7 NECROTIC CELL DEATH INDUCERS
  • 5.7.1 Progress Analysis: RAV12
  • 5.7.2 Progress Analysis: Cantuzumab mertansine
  • 5.7.3 Progress Analysis: HuC242-DM4
  • 5.7.4 Progress Analysis: COTARA
• 5.8 VACCINES: A HIGH THRESHOLD TO SUCCESS
  • 5.8.1 Cell Vaccine
  • 5.8.2 Progress Analysis: OncoVAX
  • 5.8.3 Progress Analysis CANVAXIN
  • 5.8.4 Progress analysis Collidem
  • 5.8.5 Progress Analysis Dendricell
  • 5.8.6 Progress Analysis: Neuvenge
  • 5.8.7 Progress Analysis: Onyvax-CR
  • 5.8.8 Progress Analysis: Ras-VAX
  • 5.8.9 Vaccine: Direct Immunization with Protein and peptides
  • 5.8.10 Progress Analysis Avicine
  • 5.8.11 Progress Analysis: Oncophage
  • 5.8.12 Progress Analysis EP 2101
  • 5.8.13 Progress Analysis: MSI vaccine
  • 5.8.14 Progress Analysis: Corixa's MUC-1 vaccine
  • 5.8.15 Progress Analysis: GV1002
  • 5.8.16 Anti-idiotype Monoclonal Antibodies
  • 5.8.17 Progress Analysis: CeaVac
  • 5.8.18 Progress Analysis: Onyvax-105
  • 5.8.19 DNA and Virally Encoded Vaccines
  • 5.8.20 Progress Analysis: TroVax
  • 5.8.21 Progress Analysis: ALVAC-CEA-B7.1
  • 5.8.22 Progress Analysis CEA-TRICOM
  • 5.8.23 Progress Analysis IR 705
  • 5.8.24 Progress analysis HYB-2055
  • 5.8.25 Passive Immunotherapy and Conjugated Antibodies
  • 5.8.26 Progress Analysis: IGN 101
  • 5.8.27 Progress Analysis: CEA-Cide
  • 5.8.28 Progress Analysis: LMB 9
  • 5.8.29 Progress Analysis: XR 303
  • 5.8.30 Progress Analysis ING-1
• 5.9 IMMUNO-MODULATORS
  • 5.9.1 Progress Analysis: Dacogen
  • 5.9.2 Progress Analysis: GCAN-101
  • 5.9.3 Progress Analysis: ZYC300
  • 5.9.4 Progress Analysis: Clofarabine
• 5.10 ONCOLYTIC VIROTHERAPY IN CRC - A TEAM OF FOUR
  • 5.10.1 Progress Analysis: OncoVEX
  • 5.10.2 Progress Analysis: Oncolytic HSV

6. PROSTATE CANCER

• 6.1 INTRODUCTION
  • 6.1.1 Disease Definitions
  • 6.1.2 Etiology & Pathophysiology
  • 6.1.3 Epidemiology
  • 6.1.4 Prognosis
• 6.2 CURRENT TREATMENT STRATEGIES
  • 6.2.1 Localized Disease
  • 6.2.2 Locally Advanced Prostate Cancer
  • 6.2.3 Metastatic Prostate Cancer
  • 6.2.4 Hormone-Sensitive Metastatic Prostate Cancer
  • 6.2.5 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
• 6.3 PROGRESS IN CURRENT TREATMENT STRATEGIES
  • 6.3.1 Long-Term Follow-up Data not yet Been Published
  • 6.3.2 Significant Reduced Risk of Distant Metastases
  • 6.3.3 Adverse Events
  • 6.3.4 No Difference in Overall Survival
  • 6.3.5 Cross-over Design an Optimal Option?
  • 6.3.6 Death due to Liver Failure
  • 6.3.7 Survival Benefit
  • 6.3.8 Subdermal Implant
  • 6.3.9 No FDA Approval
  • 6.3.10 No Improvement in 5-year Disease-Free Survival
  • 6.3.11 Effective Secondary Hormonal Therapy?
  • 6.3.12 Synery in Combination
• 6.4 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES
  • 6.4.1 Therapeutic Type, Targets & Mechanisms
• 6.5 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE
  • 6.5.1 Reduced Prostate Cancer Risk
  • 6.5.2 High Activity in Metastatic AIPC Patients
  • 6.5.3 Absence of Severe Toxicities
  • 6.5.4 Waiting for Data
  • 6.5.5 Probability of Regulatory Approval?
  • 6.5.6 Co-development and License Agreement
  • 6.5.7 Improves Predicted Survival?
  • 6.5.8 Slow Progress & Development Partners
  • 6.5.9 Exclusive License Agreement
• 6.6 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
  • 6.6.1 New Data?
  • 6.6.2 Terminated Study
  • 6.6.3 More Than 50% PSA decline
  • 6.6.4 Safety and Tolerability
  • 6.6.5 Terminated?
  • 6.6.6 Marker of Drug Effect
  • 6.6.7 Preliminary Results for a Tyrosine Kinase Inhibitor
  • 6.6.8 No Activity in Monotherapy
  • 6.6.9 Dramatic Disappearance of Bone Metastatic Lesions
  • 6.6.10 PSA Response - Anthracycline

7. BREAST CANCER

• 7.1 INTRODUCTION
  • 7.1.1 Clinical Practice Guidelines
  • 7.1.2 Drugs approved by FDA
• 7.2 PROGRESS IN CURRENT TREATMENT STRATEGIES
  • 7.2.1 A Hormone Therapeutic Losing Ground
  • 7.2.2 Top Three Aromatase Inhibitors
  • 7.2.3 Estrogen receptor downregulator
  • 7.2.4 Side effects & resistance
• 7.3 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
  • 7.3.1 First in New Class of Protein-Bound Particle Drugs
  • 7.3.2 High Efficacy and Reduced Cardiac Toxicity
  • 7.3.3 A chemopotentiator
  • 7.3.4 Microtubule-stabilizing agents
  • 7.3.5 A Protein kinase inhibitor in Phase III
  • 7.3.6 A bifunctional alkylating agent
  • 7.3.7 Breast Cancer Trials That Did Not Meet Primary Endpoints
• 7.4 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
  • 7.4.1 Keeping a low Profile
  • 7.4.2 Protein Kinase Inhibitors a Future Treatment or Not?
  • 7.4.3 Alimta
  • 7.4.4 A Platinum Drug With Less Toxicity
  • 7.4.5 A Proteasome Inhibitor on Track
  • 7.4.6 Antisense: An Option for Breast Cancer or Not?
  • 7.4.7 Two farnesyl transferase inhibitor making progress
• 7.5 APPENDIX B NEAR TERM "BREAST CANCER" PROGRESS
  • 7.5.1 Progress profile Abraxane
  • 7.5.2 Progress Profile Alimta
  • 7.5.3 Progress Profile Arimidex
  • 7.5.4 Progress Profile Aromasin
  • 7.5.5 Progress Profile Avastin
  • 7.5.6 Progress Profile BMS-217380-01
  • 7.5.7 Progress Profile BMS-247550
  • 7.5.8 Progress Profile CAELYX
  • 7.5.9 Progress Profile CCI-779
  • 7.5.10 Progress Profile Faslodex
  • 7.5.11 Progress Profile Femara
  • 7.5.12 Progress Profile Fenretinide
  • 7.5.13 Progress Profile Gleevec
  • 7.5.14 Progress Profile GTI-2040
  • 7.5.15 Progress Profile Herceptin
  • 7.5.16 Progress Profile Iressa
  • 7.5.17 Progress Profile ISIS-2503
  • 7.5.18 Progress Profile Lapatinib
  • 7.5.19 Progress Profile Nolvadex
  • 7.5.20 Progress Profile Sarasar
  • 7.5.21 Progress Profile SDX-105
  • 7.5.22 Progress Profile Tarceva
  • 7.5.23 Progress Profile Theratope
  • 7.5.24 Progress Profile Velcade
  • 7.5.25 Progress Profile Zarnestra
  • 7.5.26 Progress Profile Zoladex
  • 7.5.27 Progress Profile ZD0473

8. MELANOMAS

• 8.1 INTRODUCTION
  • 8.1.1 Etiology and Pathophysiology
• 8.2 CURRENT TREATMENT STRATEGIES
• 8.3 PROGRESS IN CURRENT TREATMENT STRATEGIES
• 8.4 CYTOTOXIC DRUGS
  • 8.4.1 Dacarbazine
  • 8.4.2 Cisplatin
  • 8.4.3 Carboplatin
  • 8.4.4 Carmustine
  • 8.4.5 Melphalan
  • 8.4.6 Paclitaxel
  • 8.4.7 Tamoxifen
  • 8.4.8 Temozolomide
  • 8.4.9 Vinblastine/Vinorelbine
• 8.5 BIOLOGICAL TREATMENTS
  • 8.5.1 Virulizin
  • 8.5.2 Melacine
  • 8.5.3 Alfanative (Multiferon)
  • 8.5.4 Proleukin or (Macrolin)
  • 8.5.5 Ceplene Maxamine
• 8.6 COMPETITIVE LANSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
  • 8.6.1 Phase I & II R&D Collaborations in Melanoma: Oxxon
  • 8.6.2 Roche links Schering-Plough and Chugai Clusters Together - What Will the Outcome Be?
  • 8.6.3 GlaxoSmithKline Brings Wyeth, Hayashibara, Cytokinetics and Coley Pharmaceuticals Together
  • 8.6.4 GlaxoSmithKline and Sanofi-Aventis have a Joint Middle Man
  • 8.6.5 R&D Collaboration Trends in Melanoma Projects
• 8.7 KEY THERAPY STRATEGIES
  • 8.7.1 Therapeutic Type, Targets & Mechanisms
• 8.8 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
  • 8.8.1 Vaccines: Active Immunotherapy a Benefit or Not?
  • 8.8.2 Vaccine: Direct Immunization with Tumor Antigens
  • 8.8.3 Progress Analysis: Oncophage
  • 8.8.4 Progress Analysis: GMK
  • 8.8.5 Progress Analysis: NOVOVAC-M1
  • 8.8.6 Progress Analyses: SB 249553
  • 8.8.7 Progress Analysis: MJV 101
  • 8.8.8 Progress Analysis: A Russian Melanoma Vaccine
  • 8.8.9 Progress Analysis: GV 1001
  • 8.8.10 Progress Analyses: Elea Vaccine
  • 8.8.11 Progress Analysis: NY-ESO-1 ISCOMS
  • 8.8.12 Progress Analysis: F 50040
  • 8.8.13 Progress Analysis: Transvax
  • 8.8.14 Vaccines: Is the Development of Cell Therapy Stalling?
  • 8.8.15 Progress Analysis: Canvaxin
  • 8.8.16 Progress Analysis: Dexosome
  • 8.8.17 Progress Analysis: M-VAX ORGINAL
  • 8.8.18 Progress Analysis: OncoVax
  • 8.8.19 Progress Analysis: Uvidem
  • 8.8.20 DNA Vaccine
  • 8.8.21 Progress Analysis: Alvac-Mage1/Mage3
  • 8.8.22 Progress Analysis: Oxxon Vaccine
  • 8.8.23 Progress Analysis: Therion's Melanoma Vaccine
  • 8.8.24 Progress Analysis: ImmunoVex trimelan
  • 8.8.25 Progress Analysis: OncoVEXGM-CSF
  • 8.8.26 Progress Analysis: GVAX
  • 8.8.27 Progress Analysis: Gp100 + MART-1
  • 8.8.28 Progress Analysis: MAGE-3-TK OR M3TK
  • 8.8.29 Optimism for New Vaccine Adjuvants
  • 8.8.30 Progress Analysis: Enhanzyn
  • 8.8.31 Progress Analysis: QS-21
  • 8.8.32 Progress Analysis: Zadaxin
  • 8.8.33 Progress Analysis: Mobista
  • 8.8.34 Progress Analysis: ProMune
  • 8.8.35 Progress Analysis: Talabostat
  • 8.8.36 Immunostimulants: The Push in Passive Immunotherapy
  • 8.8.37 Immuno-Biologicals: The Work Horse
  • 8.8.38 Progress Analysis: MDX-010
  • 8.8.39 Progress Analysis: Peginterferon alfa-2b
  • 8.8.40 Progress Analysis: Iboctadekin
  • 8.8.41 Progress Analysis: BAY 504798
  • 8.8.42 Progression Analysis: EMD 273063
  • 8.8.43 Progress Analysis: Urocidin
  • 8.8.44 Progress Analysis: CP-675206
  • 8.8.45 Immunostimulation by Gene Therapy
  • 8.8.46 Progress Analysis: ALLOVECTIN-7
  • 8.8.47 Inovio Biomedical Corporation and Lee Moffitt Cancer Center Make a Joint move Melanoma Gene therapy
  • 8.8.48 Progress Analysis: TG 1041
  • 8.8.49 One Small Molecular Drug Candidate
  • 8.8.50 Progress Analysis: Lenalidomide
  • 8.8.51 Antiangiogenesis- The Major Research Focus for the Next Decade?
  • 8.8.52 Progress Analysis: Sorafenib
  • 8.8.53 Progress Analysis: Vitaxin
  • 8.8.54 Progress Analysis: Avastin
  • 8.8.55 Progress Analysis: Endostatin
  • 8.8.56 Progress Analysis: PI 88
  • 8.8.57 Apoptosis Inducers: Moving into Market
  • 8.8.58 Progress Analysis: Genasense
  • 8.8.59 Progress Analysis: Didemnin B
  • 8.8.60 Progress Analysis: INGN 241
  • 8.8.61 Progress Analysis: KOS 953
  • 8.8.62 Small Molecules Inhibiting Cell Growth Faces Difficulties
  • 8.8.63 Progress Analysis: Temozolomide
  • 8.8.64 Progress Analysis: Pivanex
  • 8.8.65 Progress Analysis: Karenitecin
  • 8.8.66 Progress Analysis: Lomeguatrib
  • 8.8.67 Progress Analysis: PD 0325901
  • 8.8.68 Progress Analysis: SB 715992
  • 8.8.69 Progress Analysis: INO 1001
  • 8.8.70 Progress Analysis: CP 4055
  • 8.8.71 Other Biological Drugs
  • 8.8.72 Progress Analysis: AP 12009
  • 8.8.73 Progress Analysis: Ecromeximab
  • 8.8.74 Progress Analysis: ILX 651
  • 8.8.75 Progress Analysis: Kahalalide F
  • 8.8.76 Progress Analysis: ABX MA1

9.THE LYMPHOMAS

• 9.1 INTRODUCTION
  • 9.1.1 Disease Definition
  • 9.1.2 Etiology & Pathophysiology
  • 9.1.3 Epidemiology
  • 9.1.4 Prognosis
  • 9.1.5 Hodgkin's Disease
    • 9.1.5.1 Cellular Classification
    • 9.1.5.2 Stage Information
  • 9.1.6 Non-Hodgkin
    • 9.1.6.1 Cellular Classification
    • 9.1.6.2 Stage Information
• 9.2 CURRENT TREATMENT STRATEGIES
  • 9.2.1 Hodgkin's Disease
  • 9.2.2 Radiation Therapy
  • 9.2.3 Chemotherapy
  • 9.2.4 Transplantation
  • 9.2.5 Treatment Option Overview
  • 9.2.6 Non-Hodgkin's Lymphoma
  • 9.2.7 Radiation Therapy
  • 9.2.8 Chemotherapy
  • 9.2.9 Immunotherapy
  • 9.2.10 Bone Marrow and Peripheral Blood Transplants
  • 9.2.11 Watch and Wait
  • 9.2.12 Treatment Option Overview
• 9.3 PROGRESS IN CURRENT TREATMENT STRATEGIES
  • 9.3.1 Hodgkin
  • 9.3.2 Non-Hodgkin
  • 9.3.3 Rituxan
  • 9.3.4 Bexxar
  • 9.3.5 Zevalin
• 9.4 KEY THERAPEUTIC STRATEGIES FOR FUTURE TREATMENTS
  • 9.4.1 Therapy Type, Targets & Mechanisms
• 9.5 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
  • 9.5.1 Continous Development?
  • 9.5.2 A Pivotal Trial
  • 9.5.3 FDA Consider Granting Conditional Approval
  • 9.5.4 CR Rate of 85%
  • 9.5.5 No Longer Pursue Development
  • 9.5.6 FDA Fast Track Designation
  • 9.5.7 Long-Term Follow Up
  • 9.5.8 Prodrug Approved
  • 9.5.9 Just Small Studies
  • 9.5.10 Worldwide License
  • 9.5.11 87 Percent Overall Improvement
  • 9.5.12 Ongoing Data
  • 9.5.13 More Mabs
  • 9.5.14 Significant Clinical Activity
• 9.6 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
  • 9.6.1 Prolonged Stabilization in a Subset
  • 9.6.2 Antibody Conkugate
  • 9.6.3 Need Combinations
  • 9.6.4 Selective PKC Inhibitor
  • 9.6.5 No Grade 4 Toxicity
  • 9.6.6 More Antibodies

10. THE LEUKEMIAS

• 10.1 INTRODUCTION
  • 10.1.1 Disease Definitions
    • 10.1.1.1 The Lymphoid Malignancies
    • 10.1.1.2 The Myeloid Malignancies
  • 10.1.2 Etiology & Pathophysiology
    • 10.1.2.1 The Lymphoid Malignancies
    • 10.1.2.2 The Myeloid Malignancies
  • 10.1.3 Epidemiology
  • 10.1.4 Prognosis
    • 10.1.4.1 The Lymphoid Malignancies
    • 10.1.4.2 The Myeloid Malignancies
• 10.2 CURRENT TREATMENT STRATEGIES
  • 10.2.1 The Lymphoid Malignancies
  • 10.2.2 The Myeloid Malignancies
• 10.3 PROGRESS IN CURRENT TREATMENT STRATEGIES
  • 10.3.1 The Lymphoid Malignancies
  • 10.3.2 The Myeloid Malignancies
• 10.4 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES
  • 10.4.1 Therapeutic Type, Targets & Mechanisms
• 10.5 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
  • 10.5.1 The Lymphoid Malignancies
  • 10.5.2 Minimal Toxicity in Elderly Patients
  • 10.5.3 Increased Risk for Febrile Neutropenia
  • 10.5.4 No Conclusive Data
  • 10.5.5 The Myeloid Malignancies
  • 10.5.6 Development on Hold
  • 10.5.7 Long-Term Follow-up Data
  • 10.5.8 No Improvement in Statistically Significant Overall Response
  • 10.5.9 Approval First Half 2006
  • 10.5.10 New Data?
  • 10.5.11 Two New Phase III by Novartis
• 10.6 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
  • 10.6.1 The Myeloid Malignancies
  • 10.6.2 Flt3-ligand Inhibitors
  • 10.6.3 PKC Inhibitor With Less Toxicity?
  • 10.6.4 Still Under Development?
  • 10.6.5 Codevelopment Schering and Novartis
  • 10.6.6 Reduction in Costs
  • 10.6.7 Discontinue Clinical Trial
  • 10.6.8 Combination of Lonafarnib and Imatinib
  • 10.6.9 Effots in Antimetabolite Development
  • 10.6.10 Protease Inhibitor in 117 Abstracts
  • 10.6.11 Immunostimulant
  • 10.6.12 No new information
  • 10.6.13 The Lymphoid Malignancies
  • 10.6.14 Phosphodiesterase Inhibitor Seeking Partner
  • 10.6.15 Slow Progress
  • 10.6.16 Minor Responses
• 10.7 DRUGS APPROVED FOR THE TREATMENT OF LEUKEMIA: A HISTORICAL PERSPECTIVE

11. DISCLAIMER

• 11.1 LIABILITY
• 11.2 COMPLETENESS

12. DRUG INDEX

13. COMPANY INDEX

2.1 List Boxes

• Box 1: Quick facts on Docetaxel
• Box 2: Scientific Data on Docetaxel
• Box 3: Scientific Data on Vinorelbine
• Box 4: Quick Facts - Vinorelbine
• Box 5: Quick Facts - Gemcitabine
• Box 6: Scientific Data on Gemcitabine
• Box 7: Scientific Data on Pemetrexed
• Box 8: Quick Facts - pemetrexed
• Box 9: Quick Facts - Gefitinib
• Box 10: Scientific Data on Gefitinib
• Box 11: Quick Facts - Erlotinib
• Box 12:Example of Observed Efficacy in preclinical models
• Box 13: Anti-angiogenesis: Therapeutic strategies
• Box 14: Anti-angiogenesis: Problems that has to be solved
• Box 15: Mechanisms which tumor cells use to evade an immune reaction
• Box 16: Quick Facts - ANX-510
• Box 17: Quick Facts - Trabectedin
• Box 18: Quick Facts - Pemetrexed
• Box 19: Quick Facts - TS-1
• Box 20: Quick Facts - Edotecarin
• Box 21: Quick Facts - Aroplatin
• Box 22: Quick Facts - Ixabepilone
• Box 23: Quick Facts - Panitumumab
• Box 24: Quick Facts - Erlotinib
• Box 25: Scientific Data on Erlotinib
• Box 26: Quick Facts - Gefitinib
• Box 27: Scientific Data on Gefitinib
• Box 28: Quick Facts - Pelitinib
• Box 29: Quick Facts - Sorafenib
• Box 30: Quick Facts - BIO-117
• Box 31: Quick Facts - PD 0325901
• Box 32: Quick Facts - Vatalanib
• Box 33: Quick Facts - Thalomide
• Box 34: Quick Facts - AMG 706
• Box 35: Quick Facts - Combretastatin
• Box 36: Quick Facts - MBT 0206
• Box 37: Quick Facts - MEDI 522
• Box 38: Quick Facts - Tetrathiomolybdate
• Box 39: Quick Facts - WX-UK1
• Box 40: Quick Facts - P 54
• Box 41: Quick Facts - CV-247
• Box 42: Targets for Apoptosis Directed Therapy
• Box 43: Selection of Patents Relating to Apoptosis
• Box 44: Quick Facts - HGS-ETR1
• Box 45: Quick Facts - APLIDIN
• Box 46: Quick Facts - VELCADE
• Box 47: Millennium's License Agreement with Ortho Biotech
• Box 48: Quick Facts - TELCYTA
• Box 49: Quick Facts - EPO 906
• Box 50: Quick Facts - BIO-145
• Box 51: Quick Facts - Genasense
• Box 52: Quick Facts - Rexin-G
• Box 53: Quick Facts - Indisulam
• Box 54: Quick Facts - Seliciclib
• Box 55: Quick Facts - SYMANDEX
• Box 56: Quick Facts - RAV12
• Box 57: Quick Facts - Cantuzumab mertansine
• Box 58: Quick Facts - HuC242-DM4
• Box 59: Quick Facts - Cotara
• Box 60: Quick Facts - OncoVAX
• Box 61: Quick Facts - Canvaxin
• Box 62: Quick Facts - Collidem
• Box 63: Quick Facts - Dendricell
• Box 64: Quick Facts - Neuvenge
• Box 65: Quick Facts - Onyvax-CR
• Box 66: Quick Facts - Ras-VAX
• Box 67: Quick Facts - Avicine
• Box 68: Quick Facts - Oncophage
• Box 69: Quick Facts - EP 2101
• Box 70: Quick Facts - MSI Vaccine
• Box 71: Quick Facts - MUC-vaccine
• Box 72: Quick Facts - OncoVAX
• Box 73: Quick Facts - CeaVac
• Box 74: Quick Facts - Onyvax-105
• Box 75: Quick Facts - TroVax
• Box 76: Quick Facts - ALVA-CEA-B7.1
• Box 77: Quick Facts - CEA-TRICOM
• Box 78: Quick Facts - IR 705
• Box 79: Quick Facts - Amplivax
• Box 80: Quick Facts - IGN 101
• Box 81: Quick Facts - CEA-Cide
• Box 82: Quick Facts - LMB 9
• Box 83: Quick Facts - KSB 303
• Box 84: Quick Facts - ING-1
• Box 85: Quick Facts -Dacogen
• Box 86: Quick Facts - GCAN-101
• Box 87: Quick Facts - ZYC300
• Box 88: Quick Facts - Clofarabine
• Box 89: Quick Facts - OncoVEX
• Box 90: Quick Facts - NV 1020
• Box 91: The Eastern Cooperative Oncology Group Study
• Box 92: Southwest Oncology Group Study 99-16 Design
• Box 93: TAX 327 Study Design
• Box 94: Quick Facts - Toremifene
• Box 95: Quick Facts - Bevacizumab
• Box 96: Quick Facts - Genasense
• Box 97: Quick Facts - R-flurbiprofen
• Box 98: Quick Facts - Provenge
• Box 99: Quick Facts - Satraplatin
• Box 100: Quick Facts - GVAX
• Box 101: Quick Facts - Exisulind
• Box 102: Quick Facts - Vapreotide
• Box 103: Quick Facts - DCVax
• Box 104: Mechanisms which tumor cells use to evade an immune reaction
• Box 105: Introgen's INGN 241 Shows Vaccine Properties
• Box 106: Quick Facts - Oncophage
• Box 107: Oncophage - Designation and Status
• Box 108: Quick Facts - GM2-KLH Vaccine
• Box 109: Progenics reaquires rights to vaccine
• Box 110: Completed Melanoma Phase III trials
• Box 111: Quick Facts - NovaVac-M1
• Box 112: Quick Facts - SB 249553
• Box 113: Quick Facts - MJV 101
• Box 114: Quick Facts - Russian Melanoma Vaccine
• Box 115: Quick Facts - GV 1001
• Box 116: Quick Facts - N-Acetyl-GM3 ganglioside
• Box 117: Quick Facts: neu-glycolyl-GM3 ganglioside
• Box 118: Quick Facts - NY-ESO-1 ISCOMS
• Box 119: NY-ESO-1 and ISCOMATRIX
• Box 120: Quick Facts - F 50040
• Box 121: KpOmpA technology
• Box 122: Quick Facts - TransVax
• Box 123: Quick Facts - Canvaxin
• Box 124: Canvaxin - Designation and Status
• Box 125: CancerVax Milestone payment
• Box 126: Quick Facts - Dexosome
• Box 127: Important Milestones and License Fees
• Box 128: Quick Facts - M-VAX
• Box 129: Quick Facts -OncoVax
• Box 130: Quick Facts - Uvidem
• Box 131: Agreements Between Sanofi-Aventis and IDM
• Box 132: Quick Facts - Alvac-Mage1/Mage3
• Box 133: Quick Facts - Oxxon vaccine
• Box 134: Quick Facts - Therion's Melanoma Vaccine
• Box 135: Quick Facts - ImmunoVEX trimelan
• Box 136: Quick Facts - OncoVEX GM-CSF
• Box 137: Quick Facts - GVAX
• Box 138: Agreement Japan Tobacco and Cell Genesys
• Box 139: Predicted launch of GVAX
• Box 140: Quick Facts - Gp100 + MART-1 vaccine
• Box 141: Quick Facts - MAGE-3-TK
• Box 142: Quick Facts - Enhanzyn
• Box 143: Quick Facts - QS-21
• Box 144: Quick Facts - ZADAXIN
• Box 145: Quick Facts - Mobista
• Box 146: Quick Facts - ProMune
• Box 147: Quick Facts - Talabostat
• Box 148: Quick Facts - MDX-010
• Box 149: Quick Facts - Peginterferon alfa-2b
• Box 150:Quick Facts - BAY-504798
• Box 151: Quick Facts - EMD-273063
• Box 152: Quick Facts - Urocidin
• Box 153:Quick Facts - CP-675206
• Box 154: Quick Facts - ALLOVECTIN-7
• Box 155: Quick Facts - Cytokine, Gene therapy
• Box 156: Quick Facts - TG 1041
• Box 157: Quick Facts - Lenalidomide
• Box 158: Introgen's INGN 241 Shows Anti-angiogenesis Properties
• Box 159: Quick Facts - Sorefenib
• Box 160: Quick Facts - Vitaxin
• Box 161: Quick Facts
• Box 162: Quick Facts - Endostatin
• Box 163: Quick Facts - PI88
• Box 164: Quick Facts - Oblimersen
• Box 165: Quick Facts - Didemnin B
• Box 166: Quick Facts - INGN 241
• Box 167: Recent Identification of Molecular Pathways Underlying Activity of Introgen's INGN 241 Anti-Cancer Therapy
• Box 168: Quick Facts - KOS 953
• Box 169: Quick Facts - Temozomide
• Box 170: Molecular Pathways Underlying the Activity of Temozolomide's Anti-Cancer Therapy
• Box 171: Quick Facts - Pivanex
• Box 172: Quick Facts - Karenitecin
• Box 173: Quick Facts - Lomeguatrib
• Box 174: Quick Facts - PD 0325901
• Box 175: Quick Facts - SB 715992
• Box 176: Quick Facts - INO 1001
• Box 177: Quick Facts - CP 4055
• Box 178: Quick Facts - AP 12009
• Box 179: Quick Facts - Ecromeximab
• Box 180: Quick Facts - ILX 651
• Box 181: Quick Facts - Kahalalide F
• Box 182: Quick Facts - ABX MA1
• Box 183: Updated REAL/WHO Classification for B-Cell Neoplasms
• Box 184: Subclassification of Stage
• Box 185: Updated REAL/WHO Classification for B-Cell Neoplasms
• Box 186: Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
• Box 187: Staging Subclassification System
• Box 188: Possible Complications of Treatment
• Box 189: Study Details
• Box 190: Major Treatment Regimes
• Box 191: CLL Staging System
• Box 192: Quick Facts - Clofarabine
• Box 193: Quick Facts - Alemtuzumab
• Box 194: Quick Facts - Gemtuzumab
• Box 195: Quick Facts - Imatinib
• Box 196: Quick Facts - Rituximab
• Box 197: Quick Facts - Genasense
• Box 198: Quick Facts - Flavopiridol
• Box 199: Quick Facts - Atra
• Box 200: Quick Facts - Gvax
• Box 201: Quick Facts - Zarnestra
• Box 202: Quick Facts - BAY 43-9006
• Box 203: Quick Facts - Ceplene
• Box 204: Quick Facts - Valspodar
• Box 205: Quick Facts - CEP-701
• Box 206: Quick Facts - PKC412
• Box 207: Quick Facts - SU5416
• Box 208: Quick Facts - PTK787
• Box 209: Quick Facts - Cloretazine
• Box 210: Company Statement on Progress
• Box 211: Quick Facts - Troxacitabine
• Box 212: Quick Facts - FK228
• Box 213: Quick Facts - Decitabine
• Box 214: Quick Facts - VELCADE
• Box 215: Velcade Sales 2005
• Box 216: Quick Facts - AG-858
• Box 217: Quick Facts - Avastin
• Box 218: Quick Facts - OSI-461
• Box 219: Quick Facts - Xcytrin
• Box 220: Quick Facts - AP23573

2.2 List of Figures

• Figure 1: Summarized Description of Colon Cancer Development and Clinical Outcome
• Figure 2. Oxxon's R&D Collaborations in Melanoma
• Figure 3. Schering Plough's R&D Collaborations in Melanoma
• Figure 4. GlaxoSmithKline and Wyeth's R&D Collaborations in Melanoma
• Figure 5. Bristol-Myers Squibb's and Sanofi-Aventis' Collaborations in Melanoma
• Figure 6: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic

2.3 List Tables

• Table 1: Chemotherapeutic drugs for treatment of NSCLC
• Table 2: Near Term Approved Drugs for the Treatment of NSCLC
• Table 3: Chemotherapy Drugs off Patent
• Table 4: Generalized Illustration Depicting the Key Elements Involved in the Apoptotic Pathways
• Table 5: VTA agents under development
• Table 6: EGFR or VEGFR inhibitors
• Table 7: FMS-like tyrosine kinases and their Synonyms
• Table 8: Fms-related Tyrosine Kinase Targets in Development
• Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
• Table 10: Cancer immunotherapy strategies
• Table 11: Recently presented studies Lapatinib
• Table 12: Recently presented studies ZD-6474
• Table 13: Recently presented studies vinflunine
• Table 14: Recently presented studies Panitumumab
• Table 15: Recently presented studies Genasense
• Table 16: Recently presented studies cetuximab
• Table 17: Recently presented studies bevacizumab
• Table 18: Recently presented studies bexarotene
• Table 19: Recently presented studies Xcytrin
• Table 20: 5-year Survival Rate in CRC
• Table 21: Risk Factors for Colon Cancer Development
• Table 22: Summary of Colorectal Cancer Regimens
• Table 23: Summary of Chemotherapy Drugs
• Table 24: Capecitabine - Major Developmental Milestones
• Table 25: Ironotecan - Major Developmental Milestones
• Table 26: Bevacizumab - Major Developmental Milestones
• Table 27: Sales Predictions on Bevacizumab
• Table 28: Oxaliplatin - Major Developmental Milestones
• Table 29: Cetuximab - Major Developmental Milestones
• Table 30: Sales Predictions on Cetuximab
• Table 31: Common Gene/Protein Defects in Apoptotic Pathways
• Table 32: A Selection of Apoptosis Targets in Development
• Table 33: Selection of VTA agents under clinical development as cancer therapeutics
• Table 34: Colorectal Cancer Vaccines in Development
• Table 35: The Representation of Investigators in the CRC Drug Pipeline
• Table 36: Drugs with Four or more Investigators
• Table 37: Phase III Competitors
• Table 38: Industrial Investigators with the Highest Number of CRC Drugs in Phase I to Phase III development
• Table 39: Phase I - Phase III Chemotherapy and Cytotoxic Drugs in Development
• Table 40: Phase I-Phase III EGF-R Inhibitors as CRC Therapeutics
• Table 41: Phase I-Phase III Signal Transduction Inhibitors in CRC
• Table 42: Phase I - Phase III Antiangiogenic Drugs in Development
• Table 43: Current COX-2 Inhibitors in Development
• Table 44: Apoptotic Cell Death Inducers in Development
• Table 45: Necrotic Cell Death Inducers in Development
• Table 46 Cell therapy based platform in pipeline as potential treatment of colorectal cancer
• Table 47: Protein/peptide vaccine as potential treatment of colorectal cancer
• Table 48: Anti-idiotype monoclonal antibodies
• Table 49: Nucleic acid and virally encoded vaccines
• Table 50: Monoclonal Antibodies
• Table 51: Immuno-modulators in CRC
• Table 52: The TNM System
• Table 53: Lifestyle factors
• Table 54: Historical Summary of Clinical Studies on Patients with Late Stage Disease
• Table 55: Short Facts Abarelix
• Table 56: Short Facts Bicalutamide
• Table 57: Short Facts Carboplatin
• Table 58: Short Facts Docetaxel
• Table 59: Short Facts Mitoxantrone
• Table 60: Short Facts Flutamide
• Table 61: Short Facts Goserelin
• Table 62: Short Facts Histrelin
• Table 63: Short Facts Lanreotide
• Table 64: Short Facts Leuprolide
• Table 65: Short Facts Nilutamide
• Table 66: Short Facts Estramustine
• Table 67: Summary of Recent Clinical Studies on Patients with Late Stage Disease
• Table 68: Ongoing Late Stage Clinical Studies
• Table 69: Cancer Immunotherapy Strategies
• Table 70: Near Term Progress Toremifene
• Table 71: Near Term Progress Bevacizumab
• Table 72: Near Term Progress Oblimersen
• Table 73: Near Term Progress R-flurbiprofen
• Table 74: Near Term Progress APC8015
• Table 75: Near Term Progress Satraplatin
• Table 76: Near Term Progress GVAX
• Table 77: Near Term Progress Exisulind
• Table 78: Summary of Prostate Cancer Late Stage Pipeline
• Table 79: Paclitaxel
• Table 80: Epothilone
• Table 81: Ixabepilone
• Table 82: PTK/ZK
• Table 83: Arsenic trioxide
• Table 84: Retinoic Acid
• Table 85: Imatinib
• Table 86: Bortezomib
• Table 87: Sorafenib
• Table 88: Doxorubicin
• Table 89: Summary of Prostate Cancer Early Stage Pipeline
• Table 90: Summary of Mid-Stage to Late stage Investigational Agents Under Development for the Treatment of Breast Cancer
• Table 91: Critical Risk Factors for Development of Melanoma
• Table 92: Definition and Description of Stages of Melanoma
• Table 93: Prognosis of the 4 Stages of Malignant Melanoma
• Table 94: Current Cytotoxic Drugs for Treatment of Melanoma
• Table 95: Development Milestones- Virulizin
• Table 96: Development Milestones - Melacine
• Table 97: Development Milestones - Alfanative
• Table 98: Development Milestones - Proleukin
• Table 99: Number of Collaborations and Drugs per Developmental Stage
• Table 100: Deployed Strategies for Blocking Angiogenesis
• Table 101: Tumor antigen
• Table 102: In vivo gene therapy
• Table 103: Cell therapy based platform in pipeline as potential treatment of melanoma
• Table 104: Ex vivo gene therapy loading of antigen presenting cells
• Table 105: Overview of Immunostimulants in Development based on Type
• Table 106: Overview of Immuno-Biologicals
• Table 107: MDX-010's Collaborative History and Landscape
• Table 108: Overview of Gene Therapy Drugs for Immunostimulation
• Table 109: Anti-angiogenisis Drugs under Development
• Table 110:Selected Regulatory Progress of Sorafenib
• Table 111: Overview Apoptopic Inducer Drugs
• Table 112: Selected Regulatory Progress of Didemin B
• Table 113: Overview of Small Molecule Drugs
• Table 114: Overview of Various Biological Drugs in Development for Melanoma
• Table 115: Drugs Used in the Treatment of Lymphoma
• Table 116: Summary of Strategies Enhancing Antibody Function
• Table 117: Cancer Immunotherapy Strategies
• Table 118: Protein Kinase Targets in Clinical Trials for Lymphoma
• Table 119: Near Term Progress Aldesleukin
• Table 120: Near Term Progress Arsenic trioxide
• Table 121: Near Term Progress BiovaxID
• Table 122: Near Term Progress Bortezomib
• Table 123: Near Term Progress Epratuzumab
• Table 124: Near Term Progress FavId
• Table 125: Near Term Progress MyVax
• Table 126: Near Term Progress Nelarabine
• Table 127: Near Term Progress Genasense
• Table 128: Near Term Progress Pixantrone
• Table 129: Near Term Progress Temsirolimus
• Table 130: Near Term Progress Zanolimumab
• Table 131: Near Term Progress Flavopiridol
• Table 132: Near Term Progress Bevacizumab
• Table 133: Near Term Progress CMC-544
• Table 134: Near Term Progress Galiximab
• Table 135: Near Term Progress LY317615
• Table 136: Near Term Progress SGN-40
• Table 137: Near Term Progress Apolizumab
• Table 138: Near Term Progress SGN-30
• Table 139: ALL Classification
• Table 140: Latest Approved Drugs for the Treatment of Leukemia
• Table 141: Kinase Inhibitors in Development for the Treatment of Leukemia
• Table 142: Near Term Progress Rituximab
• Table 143: Near Term Progress Oblimersen
• Table 144: Near Term Progress Alvocidib
• Table 145: Near Term Progress ATRA
• Table 146: Near term progress GVAX
• Table 147: Near tearm progress HuM195
• Table 148: Near term progress Zarnestra
• Table 149: Near Term Progress Sorafenib
• Table 150: Near Term Progress Valspodar
• Table 151: Summary of Current Late Stage Pipeline
• Table 152: Near term progress CEP-701
• Table 153: Near Term Progress PKC412
• Table 154: Near Term Progress SU5416
• Table 155: Near Term Progress PTK787
• Table 156: Near Term Progress VNP40101M
• Table 157: Near Term Progress Troxacitabine
• Table 158: Near Term Progress Decitabine
• Table 159: Near Term Progress Bortezomib
• Table 160: Near Term Progress AG-858
• Table 161: Near Term Progress Bevacizumab
• Table 162: Near Term Progress OSI-461
• Table 163: Near Term Progress Xcytrin
• Table 164: Near Term Progress AP23573
• Table 165: Summary of Current Early Stage Pipeline